Literature DB >> 34326429

Comprehensive virtual screening of 4.8 k flavonoids reveals novel insights into allosteric inhibition of SARS-CoV-2 MPRO.

Gabriel Jiménez-Avalos1, A Paula Vargas-Ruiz2, Nicolás E Delgado-Pease2, Gustavo E Olivos-Ramirez2, Patricia Sheen2, Manolo Fernández-Díaz3, Miguel Quiliano4, Mirko Zimic5,6.   

Abstract

SARS-CoV-2 main protease is a common target for inhibition assays due to its high conservation among coronaviruses. Since flavonoids show antiviral activity, several in silico works have proposed them as potential SARS-CoV-2 main protease inhibitors. Nonetheless, there is reason to doubt certain results given the lack of consideration for flavonoid promiscuity or main protease plasticity, usage of short library sizes, absence of control molecules and/or the limitation of the methodology to a single target site. Here, we report a virtual screening study where dorsilurin E, euchrenone a11, sanggenol O and CHEMBL2171598 are proposed to inhibit main protease through different pathways. Remarkably, novel structural mechanisms were observed after sanggenol O and CHEMBL2171598 bound to experimentally proven allosteric sites. The former drastically affected the active site, while the latter triggered a hinge movement which has been previously reported for an inactive SARS-CoV main protease mutant. The use of a curated database of 4.8 k flavonoids, combining two well-known docking software (AutoDock Vina and AutoDock4.2), molecular dynamics and MMPBSA, guaranteed an adequate analysis and robust interpretation. These criteria can be considered for future screening campaigns against SARS-CoV-2 main protease.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34326429     DOI: 10.1038/s41598-021-94951-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  72 in total

1.  CryptoSite: Expanding the Druggable Proteome by Characterization and Prediction of Cryptic Binding Sites.

Authors:  Peter Cimermancic; Patrick Weinkam; T Justin Rettenmaier; Leon Bichmann; Daniel A Keedy; Rahel A Woldeyes; Dina Schneidman-Duhovny; Omar N Demerdash; Julie C Mitchell; James A Wells; James S Fraser; Andrej Sali
Journal:  J Mol Biol       Date:  2016-02-05       Impact factor: 5.469

2.  X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.

Authors:  Sebastian Günther; Patrick Y A Reinke; Yaiza Fernández-García; Julia Lieske; Thomas J Lane; Helen M Ginn; Faisal H M Koua; Christiane Ehrt; Wiebke Ewert; Dominik Oberthuer; Oleksandr Yefanov; Susanne Meier; Kristina Lorenzen; Boris Krichel; Janine-Denise Kopicki; Luca Gelisio; Wolfgang Brehm; Ilona Dunkel; Brandon Seychell; Henry Gieseler; Brenna Norton-Baker; Beatriz Escudero-Pérez; Martin Domaracky; Sofiane Saouane; Alexandra Tolstikova; Thomas A White; Anna Hänle; Michael Groessler; Holger Fleckenstein; Fabian Trost; Marina Galchenkova; Yaroslav Gevorkov; Chufeng Li; Salah Awel; Ariana Peck; Miriam Barthelmess; Frank Schlünzen; P Lourdu Xavier; Nadine Werner; Hina Andaleeb; Najeeb Ullah; Sven Falke; Vasundara Srinivasan; Bruno Alves França; Martin Schwinzer; Hévila Brognaro; Cromarte Rogers; Diogo Melo; Joanna J Zaitseva-Doyle; Juraj Knoska; Gisel E Peña-Murillo; Aida Rahmani Mashhour; Vincent Hennicke; Pontus Fischer; Johanna Hakanpää; Jan Meyer; Philip Gribbon; Bernhard Ellinger; Maria Kuzikov; Markus Wolf; Andrea R Beccari; Gleb Bourenkov; David von Stetten; Guillaume Pompidor; Isabel Bento; Saravanan Panneerselvam; Ivars Karpics; Thomas R Schneider; Maria Marta Garcia-Alai; Stephan Niebling; Christian Günther; Christina Schmidt; Robin Schubert; Huijong Han; Juliane Boger; Diana C F Monteiro; Linlin Zhang; Xinyuanyuan Sun; Jonathan Pletzer-Zelgert; Jan Wollenhaupt; Christian G Feiler; Manfred S Weiss; Eike-Christian Schulz; Pedram Mehrabi; Katarina Karničar; Aleksandra Usenik; Jure Loboda; Henning Tidow; Ashwin Chari; Rolf Hilgenfeld; Charlotte Uetrecht; Russell Cox; Andrea Zaliani; Tobias Beck; Matthias Rarey; Stephan Günther; Dusan Turk; Winfried Hinrichs; Henry N Chapman; Arwen R Pearson; Christian Betzel; Alke Meents
Journal:  Science       Date:  2021-04-02       Impact factor: 47.728

Review 3.  The SARS-CoV-2 main protease as drug target.

Authors:  Sven Ullrich; Christoph Nitsche
Journal:  Bioorg Med Chem Lett       Date:  2020-07-02       Impact factor: 2.823

4.  SARS-CoV-2 Main Protease: A Molecular Dynamics Study.

Authors:  Dimas Suárez; Natalia Díaz
Journal:  J Chem Inf Model       Date:  2020-08-03       Impact factor: 4.956

5.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors.

Authors:  Linlin Zhang; Daizong Lin; Xinyuanyuan Sun; Ute Curth; Christian Drosten; Lucie Sauerhering; Stephan Becker; Katharina Rox; Rolf Hilgenfeld
Journal:  Science       Date:  2020-03-20       Impact factor: 47.728

6.  An interactive web-based dashboard to track COVID-19 in real time.

Authors:  Ensheng Dong; Hongru Du; Lauren Gardner
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

Review 7.  Hierarchical virtual screening approaches in small molecule drug discovery.

Authors:  Ashutosh Kumar; Kam Y J Zhang
Journal:  Methods       Date:  2014-07-27       Impact factor: 3.608

Review 8.  From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design.

Authors:  Rolf Hilgenfeld
Journal:  FEBS J       Date:  2014-08-11       Impact factor: 5.542

9.  Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site.

Authors:  Jaeyong Lee; Liam J Worrall; Marija Vuckovic; Federico I Rosell; Francesco Gentile; Anh-Tien Ton; Nathanael A Caveney; Fuqiang Ban; Artem Cherkasov; Mark Paetzel; Natalie C J Strynadka
Journal:  Nat Commun       Date:  2020-11-18       Impact factor: 14.919

10.  Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease.

Authors:  Alice Douangamath; Daren Fearon; Paul Gehrtz; Tobias Krojer; Petra Lukacik; C David Owen; Efrat Resnick; Claire Strain-Damerell; Anthony Aimon; Péter Ábrányi-Balogh; José Brandão-Neto; Anna Carbery; Gemma Davison; Alexandre Dias; Thomas D Downes; Louise Dunnett; Michael Fairhead; James D Firth; S Paul Jones; Aaron Keeley; György M Keserü; Hanna F Klein; Mathew P Martin; Martin E M Noble; Peter O'Brien; Ailsa Powell; Rambabu N Reddi; Rachael Skyner; Matthew Snee; Michael J Waring; Conor Wild; Nir London; Frank von Delft; Martin A Walsh
Journal:  Nat Commun       Date:  2020-10-07       Impact factor: 14.919

View more
  7 in total

Review 1.  Methodology-Centered Review of Molecular Modeling, Simulation, and Prediction of SARS-CoV-2.

Authors:  Kaifu Gao; Rui Wang; Jiahui Chen; Limei Cheng; Jaclyn Frishcosy; Yuta Huzumi; Yuchi Qiu; Tom Schluckbier; Xiaoqi Wei; Guo-Wei Wei
Journal:  Chem Rev       Date:  2022-05-20       Impact factor: 72.087

2.  Identifying RO9021 as a Potential Inhibitor of PknG from Mycobacterium tuberculosis: Combinative Computational and In Vitro Studies.

Authors:  Alicia Arica-Sosa; Roberto Alcántara; Gabriel Jiménez-Avalos; Mirko Zimic; Pohl Milón; Miguel Quiliano
Journal:  ACS Omega       Date:  2022-05-31

Review 3.  Predicting global diet-disease relationships at the atomic level: a COVID-19 case study.

Authors:  Lennie Ky Cheung; Rickey Y Yada
Journal:  Curr Opin Food Sci       Date:  2022-01-03       Impact factor: 9.800

Review 4.  Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?

Authors:  Theoharis C Theoharides
Journal:  Mol Neurobiol       Date:  2022-01-13       Impact factor: 5.682

Review 5.  Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents.

Authors:  Lara Alzyoud; Mohammad A Ghattas; Noor Atatreh
Journal:  Drug Des Devel Ther       Date:  2022-08-02       Impact factor: 4.319

6.  Commercially Available Flavonols Are Better SARS-CoV-2 Inhibitors than Isoflavone and Flavones.

Authors:  Otávio Augusto Chaves; Natalia Fintelman-Rodrigues; Xuanting Wang; Carolina Q Sacramento; Jairo R Temerozo; André C Ferreira; Mayara Mattos; Filipe Pereira-Dutra; Patrícia T Bozza; Hugo Caire Castro-Faria-Neto; James J Russo; Jingyue Ju; Thiago Moreno L Souza
Journal:  Viruses       Date:  2022-06-30       Impact factor: 5.818

7.  Potential SARS-CoV-2 3CLpro inhibitors from chromene, flavonoid and hydroxamic acid compound based on FRET assay, docking and pharmacophore studies.

Authors:  Maywan Hariono; Pandu Hariyono; Rini Dwiastuti; Wahyuning Setyani; Muhammad Yusuf; Nurul Salin; Habibah Wahab
Journal:  Results Chem       Date:  2021-09-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.